Skip to main content
SpringerLink
Log in

Definition and Epidemiology of Antiphospholipid Syndrome

  • Chapter
  • First Online:
Antiphospholipid Syndrome

Abstract

Accurate definition and epidemiology of a disease are the first steps to understand clinical and global burden of a disease. Although antiphospholipid syndrome (APS) has a clear definition for classification of patients with a limited spectrum of clinical and laboratory criteria, a broader spectrum of clinical manifestations exists, and thrombosis may be multifactorial. A standard definition of APS is challenging. Although data on epidemiology of APS are limited, being based on small scale studies or studies with methodological limitations, this chapter gives the best synthesis possible today.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheumatol. 1999;42:1309–11.

    Article  CAS  Google Scholar 

  2. Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheumatol. 2000;43:440–3.

    Article  CAS  Google Scholar 

  3. Weber M, Hayem G, Meyer O. The Sapporo criteria for antiphospholipid syndrome: comment on the article by Lockshin et al. Arthritis Rheumatol. 2001;44:1965–6.

    Article  CAS  Google Scholar 

  4. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.

    Article  CAS  PubMed  Google Scholar 

  5. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A. 1991;88:3069–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Pierangeli SS, Liu XW, Barker JH, Anderson G, Harris EN. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost. 1995;74:1361–7.

    CAS  PubMed  Google Scholar 

  7. Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome. J Rheumatol. 1992;19:1778–81.

    CAS  PubMed  Google Scholar 

  8. Alarcon-Segovia D, Perez-Vazquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum. 1992;21:275–86.

    Article  CAS  PubMed  Google Scholar 

  9. Barbhaiya M, Amigo M, Avcin T, Bertolaccini M, Branch W, et al. Development of new international classification criteria for antiphospholipid syndrome: needs assessment assay [abstract]. Lupus. 2016;25:67.

    Google Scholar 

  10. Abdel-Wahab N, Lopez-Olivo MA, Pinto-Patarroyo GP, Suarez-Almazor ME. Systematic review of case reports of antiphospholipid syndrome following infection. Lupus. 2016;25:1520–31.

    Article  CAS  PubMed  Google Scholar 

  11. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827–32.

    Article  CAS  PubMed  Google Scholar 

  12. Reynaud Q, Lega JC, Mismetti P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2014;13:595–608.

    Article  CAS  PubMed  Google Scholar 

  13. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus: a meta-analysis. Lupus. 1997;6:467–73.

    Article  CAS  PubMed  Google Scholar 

  14. Wahl DG, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus. 1998;7:15–22.

    Article  CAS  PubMed  Google Scholar 

  15. Zuily S, Regnault V, Selton-Suty C, et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation. 2011;124:215–24.

    Article  CAS  PubMed  Google Scholar 

  16. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8:237–42.

    Article  CAS  PubMed  Google Scholar 

  17. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118:4714–8.

    Article  CAS  PubMed  Google Scholar 

  18. Murer LM, Pirruccello SJ, Koepsell SA. Rivaroxaban therapy, false-positive lupus anticoagulant screening results, and confirmatory assay results. Lab Med. 2016;47:275–8.

    Article  PubMed  Google Scholar 

  19. Vlagea A, Gil A, Cuesta MV, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential markers of antiphospholipid syndrome. Clin Appl Thromb Hemost. 2013;19:289–96.

    Article  CAS  PubMed  Google Scholar 

  20. Unlu O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. 2016;3:75–84.

    Article  PubMed  Google Scholar 

  21. Zuily S, Wahl D. Increased risk for pulmonary hypertension associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: a meta-analysis of echocardiographic studies. J Thromb Haemost. 2015;13:166–7.

    Google Scholar 

  22. Abreu MM, Danowski A, Wahl DG, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14:401–14.

    Article  PubMed  Google Scholar 

  23. Pardos-Gea J, Avegliano G, Evangelista A, Vilardell M, Ordi-Ros J. Cardiac manifestations other than valvulopathy in antiphospholipid syndrome: long-time echocardiography follow-up study. Int J Rheum Dis. 2015;18:76–83.

    Article  PubMed  Google Scholar 

  24. Matyja-Bednarczyk A, Swadzba J, Iwaniec T, et al. Risk factors for arterial thrombosis in antiphospholipid syndrome. Thromb Res. 2014;133:173–6.

    Article  CAS  PubMed  Google Scholar 

  25. Vaillant L, Larmande P, Arbeille B, Desveaux B, Gruel Y, Lorette G. Livedo reticularis, cerebrovascular disorders and mitral disease: a new cause of Sneddon’s syndrome? Ann Dermatol Venereol. 1990;117:925–30.

    CAS  PubMed  Google Scholar 

  26. Viall CA, Chamley LW. Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature. Autoimmun Rev. 2015;14:446–71.

    Article  CAS  PubMed  Google Scholar 

  27. Nochy D, Daugas E, Droz D, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol. 1999;10:507–18.

    CAS  PubMed  Google Scholar 

  28. Qu H, Shewchuk RM, Alarcon G, et al. Mapping perceptions of lupus medication decision-making facilitators: the importance of patient context. Arthritis Care Res. 2016;68:1787–94.

    Article  Google Scholar 

  29. Zuily S, Wahl D, Erkan D. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository cluster analysis for identification of different clinical phenotypes among antiphospholipid antibody-positive patients. Lupus. 2016;25:74–5.

    Google Scholar 

  30. Zuily S, Chighizola CB, Baumann C, Meroni PL, Erkan D. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository cluster analysis for the identification of different clinical phenotypes among antiphospholipid antibody-positive female patients with a history of pregnancy. Lupus. 2016;25:61.

    Article  CAS  Google Scholar 

  31. Nilsson IM, Astedt B, Hedner U, Berezin D. Intrauterine death and circulating anticoagulant (“antithromboplastin”). Acta Med Scand. 1975;197:153–9.

    Article  CAS  PubMed  Google Scholar 

  32. Abou-Nassar K, Carrier M, Ramsay T, Rodger MA. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res. 2011;128:77–85.

    Article  CAS  PubMed  Google Scholar 

  33. Silver RM, Parker CB, Reddy UM, et al. Antiphospholipid antibodies in stillbirth. Obstet Gynecol. 2013;122:641–57.

    Article  CAS  PubMed  Google Scholar 

  34. Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthrit Rheumatol. 2012;64:2311–8.

    Article  CAS  Google Scholar 

  35. Simpson JL, ERM J. Early pregnancy loss and stillbirth. In: Gabbe SG, editor. Obstetrics – normal and problem pregnancies. 7th ed. Philadelphia: Elsevier; 2017. p. 579.

    Google Scholar 

  36. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785–99.

    Article  PubMed  Google Scholar 

  37. de Jesús GR, Rodrigues G, de Jesús NR, Levy RA. Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? Curr Rheumatol Rep. 2014;16:403.

    Article  PubMed  CAS  Google Scholar 

  38. do Prado AD, Piovesan DM, Staub HL, Horta BL. Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis. Obstet Gynecol. 2010;116:1433–43.

    Article  PubMed  Google Scholar 

  39. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122–31.

    Article  Google Scholar 

  40. American College of Obstetricians and Gynecologists. Practice bulletin no. 134. Obstet Gynecol. 2013;121:1122–33.

    Article  Google Scholar 

  41. Serrano F, Nogueira I, Borges A, Branco J. Primary antiphospholipid syndrome: pregnancy outcome in a portuguese population. Acta Reumatol Port. 2009;34:492–7.

    PubMed  Google Scholar 

  42. Grande M, Borrell A, Garcia-Posada R, et al. The effect of maternal age on chromosomal anomaly rate and spectrum in recurrent miscarriage. Hum Reprod. 2012;27:3109–17.

    Article  PubMed  Google Scholar 

  43. Sugiura-Ogasawara M, Ozaki Y, Katano K, Suzumori N, Kitaori T, Mizutani E. Abnormal embryonic karyotype is the most frequent cause of recurrent miscarriage. Hum Reprod. 2012;27:2297–303.

    Article  PubMed  Google Scholar 

  44. de Jesus GR, Agmon-Levin N, Andrade CA, et al. 14th international congress on antiphospholipid antibodies task force report on obstetric antiphospholipid syndrome. Autoimmun Rev. 2014;13:795–813.

    Article  PubMed  Google Scholar 

  45. Wong L, Porter T, Gd J. Recurrent early pregnancy loss and antiphospholipid antibodies: where do we stand? Lupus. 2014;23:1226–8.

    Article  CAS  PubMed  Google Scholar 

  46. Sibai BM. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing? Am J Obstet Gynecol. 1990;162:311–6.

    Article  CAS  PubMed  Google Scholar 

  47. Pourrat O, Coudroy R, Pierre F. Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators. Eur J Obstet Gynecol Reprod Biol. 2015;189:68–72.

    Article  CAS  PubMed  Google Scholar 

  48. George D, Vasanth L, Erkan D, Bass A, Salmon J, Lockshin MD. Primary antiphospholipid syndrome presenting as HELLP syndrome: a clinical pathology conference held by the Division of Rheumatology at Hospital for Special Surgery. HSS J. 2007;3:216–21.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Mekinian A, Loire-Berson P, Nicaise-Roland P, et al. Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels. J Reprod Immunol. 2012;94:222–6.

    Article  PubMed  Google Scholar 

  50. Simchen MJ, Dulitzki M, Rofe GUY, et al. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand. 2011;90:1428–33.

    Article  PubMed  Google Scholar 

  51. Ramires de Jesús G, Levy RA, Porter TF, Branch DW. Limited evidence for diagnosing and treating “non-criteria obstetric antiphospholipid syndrome”. Thromb Haemost. 2015;114:651–2.

    Article  PubMed  Google Scholar 

  52. Chighizola CB, de Jesus GR, Branch DW. The hidden world of anti-phospholipid antibodies and female infertility: a literature appraisal. Autoimmun Rev. 2016;15:493–500.

    Article  CAS  PubMed  Google Scholar 

  53. Bertolaccini ML, Amengual O, Andreoli L, et al. 14th international congress on antiphospholipid antibodies task force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014;13:917–30.

    Article  PubMed  Google Scholar 

  54. Practice Committee of American Society for Reproductive Medicine. Anti-phospholipid antibodies do not affect IVF success. Fertil Steril. 2008;90:172–S3.

    Google Scholar 

  55. Pritchard JA, Cunningham FG, Pritchard SA, Mason RA. On reducing the frequency of severe abruptio placentae. Am J Obstet Gynecol. 1991;165:1345–51.

    Article  CAS  PubMed  Google Scholar 

  56. Kitchens CS, Erkan D, Brandao LR, et al. Thrombotic storm revisited: preliminary diagnostic criteria suggested by the thrombotic storm study group. Am J Med. 2011;124:290–6.

    Article  PubMed  Google Scholar 

  57. Asherson RA. New subsets of the antiphospholipid syndrome in 2006: “PRE-APS” (probable APS) and microangiopathic antiphospholipid syndromes (“MAPS”). Autoimmun Rev. 2006;6:76–80.

    Article  PubMed  Google Scholar 

  58. Asherson RA, Cervera R. Microvascular and microangiopathic antiphospholipid-associated syndromes (“MAPS”): semantic or antisemantic? Autoimmun Rev. 2008;7:164–7.

    Article  CAS  PubMed  Google Scholar 

  59. Asherson RA, Cervera R, Merrill JT. Thrombotic microangiopathic antiphospholipid syndromes: a continuum of conditions? Fut Rheumatol. 2006;1:355–64.

    Article  Google Scholar 

  60. Asherson RA, Pierangeli S, Cervera R. Microangiopathic antiphospholipid-associated syndromes revisited new concepts relating to antiphospholipid antibodies and syndromes. J Rheumatol. 2007;34:1793–5.

    PubMed  Google Scholar 

  61. Asherson RA, Pierangeli SS, Cervera R. Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis. 2007;66:429–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Cervera R, Rodriguez-Pinto I. Catastrophic antiphospholipid syndrome: task force report summary. Lupus. 2014;23:1283–5.

    Article  PubMed  Google Scholar 

  63. Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530–4.

    Article  CAS  PubMed  Google Scholar 

  64. Aguiar CL, Erkan D. Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease. Ther Adv Musculoskelet Dis. 2013;5:305–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine. 1998;77:195–207.

    Article  CAS  PubMed  Google Scholar 

  66. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine. 2001;80:355–77.

    Article  CAS  PubMed  Google Scholar 

  67. Cervera R, Bucciarelli S, Plasin MA, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmun. 2009;32:240–5.

    Article  CAS  PubMed  Google Scholar 

  68. Cervera R, Boffa MC, Khamashta MA, Hughes GR. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus. 2009;18:889–93.

    Article  CAS  PubMed  Google Scholar 

  69. Peschken CA, Katz SJ, Silverman E, et al. The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. J Rheumatol. 2009;36:1200–8.

    Article  PubMed  Google Scholar 

  70. Faden D, Tincani A, Tanzi P, et al. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-beta2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. Eur J Obstet Gynecol Reprod Biol. 1997;73:37–42.

    Article  CAS  PubMed  Google Scholar 

  71. Creagh M, Duncan S, McDonnell J, Greaves M. Failure of the detection of antiphospholipid antibodies alone to predict poor pregnancy outcome. Br J Haematol. 1991;77:4.

    Google Scholar 

  72. Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res. 2013;65:1869–73.

    Article  CAS  Google Scholar 

  73. Sciascia S, Sanna G, Khamashta MA, et al. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann Rheum Dis. 2015;74:2028–33.

    Article  CAS  PubMed  Google Scholar 

  74. Taraborelli M, Leuenberger L, Lazzaroni MG, et al. The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus. Lupus. 2016;25:1365–8.

    Article  CAS  PubMed  Google Scholar 

  75. Mok MY, Chan EY, Fong DY, Leung KF, Wong WS, Lau CS. Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J Rheumatol. 2005;32:622–8.

    CAS  PubMed  Google Scholar 

  76. Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev. 2010;9:299–304.

    Article  Google Scholar 

  77. de Carvalho JF. Influence of gender on the clinical and laboratory spectra of patients with primary antiphospholipid syndrome. Rheumatol Int. 2011;31:647–50.

    Article  CAS  PubMed  Google Scholar 

  78. Jara LJ, Medina G, Vera-Lastra O, Barile L. The impact of gender on clinical manifestations of primary antiphospholipid syndrome. Lupus. 2005;14:607–12.

    Article  CAS  PubMed  Google Scholar 

  79. Uthman I, Khamashta M. Ethnic and geographical variation in antiphospholipid (Hughes) syndrome. Ann Rheum Dis. 2005;64:1671–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Diri E, Cucurull E, Gharavi AE, et al. Antiphospholipid (Hughes’) syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype. Lupus. 1999;8:263–8.

    Article  CAS  PubMed  Google Scholar 

  81. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology. 2002;41:924–9.

    Article  CAS  PubMed  Google Scholar 

  82. Kaul M, Erkan D, Sammaritano L, Lockshin MD. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2007;66:927–30.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis. 2003;62:388–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Blank M, Asherson RA, Cervera R, Shoenfeld Y. Antiphospholipid syndrome infectious origin. J Clin Immunol. 2004;24:12–23.

    Article  CAS  PubMed  Google Scholar 

  85. Loizou S, Cazabon JK, Walport MJ, Tait D, So AK. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheumatol. 1997;40:103–8.

    Article  CAS  Google Scholar 

  86. Murthy PK. Current epidemiology of leprosy. J Indian Med Assoc. 2004;102:672–3. 83

    PubMed  Google Scholar 

  87. Karadeniz A, Lally L, Magro C, Levy R, Erkan D, Lockshin MD. Lepromatous leprosy mimicking systemic lupus erythematosus: a clinical pathology conference held by the division of rheumatology at hospital for special surgery. HSS J. 2014;10:286–91.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Arvieux J, Renaudineau Y, Mane I, Perraut R, Krilis SA, Youinou P. Distinguishing features of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Thromb Haemost. 2002;87:599–605.

    CAS  PubMed  Google Scholar 

  89. Baeza I, Wong-Baeza C, Valerdi E, et al. Lepromatous leprosy patients produce antibodies that recognise non-bilayer lipid arrangements containing mycolic acids. Mem Inst Oswaldo Cruz. 2012;107:95–103.

    Article  CAS  PubMed  Google Scholar 

  90. Forastiero RR, Martinuzzo ME, de Larranaga GF. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus. 2005;14:129–36.

    Article  CAS  PubMed  Google Scholar 

  91. Hojnik M, Gilburd B, Ziporen L, et al. Anticardiolipin antibodies in infections are heterogenous in their dependency on beta 2-glycoprotein I: analysis of anticardiolipin antibodies in leprosy. Lupus. 1994;3:515–21.

    Article  CAS  PubMed  Google Scholar 

  92. Azulay-Abulafia L, Pereira Spinelli L, Hardmann D, et al. Lucio phenomenon. Vasculitis or occlusive vasculopathy? Hautarzt. 2006;57:1101–5.

    Article  CAS  PubMed  Google Scholar 

  93. Alpsoy E. Behcet’s disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol. 2016;43:620–32.

    Article  CAS  PubMed  Google Scholar 

  94. Murakami M, Yoshimura K, Sugiya H, et al. Fluid and amylase secretion by perfused parotid gland: physio-morphological approach. J Korean Med Sci. 2000;15:38–9.

    Article  Google Scholar 

  95. Alekberova ZS, Prokaeva TB, Reshetniak TM, Aleksandrova EN, Nasonov EL. Antiphospholipid antibodies in Behcet’s disease. Klin Med (Mosk). 2000;78:37–8.

    CAS  Google Scholar 

  96. Tokay S, Direskeneli H, Yurdakul S, Akoglu T. Anticardiolipin antibodies in Behcet’s disease: a reassessment. Rheumatology. 2001;40:192–5.

    Article  CAS  PubMed  Google Scholar 

  97. Hughes JP, Stovin PG. Segmental pulmonary artery aneurysms with peripheral venous thrombosis. Br J Dis Chest. 1959;53:19–27.

    Article  CAS  PubMed  Google Scholar 

  98. Durieux P, Bletry O, Huchon G, Wechsler B, Chretien J, Godeau P. Multiple pulmonary arterial aneurysms in Behcet’s disease and Hughes-Stovin syndrome. Am J Med. 1981;71:736–41.

    Article  CAS  PubMed  Google Scholar 

  99. Francois MF. Is Hughes-Stovin syndrome a particular expression of Behcet’s disease? Chest. 1983;83:288.

    Article  CAS  PubMed  Google Scholar 

  100. Erkan D, Yazici Y, Sanders A, Trost D, Yazici H. Is Hughes-Stovin syndrome Behcet’s disease? Clin Exp Rheumatol. 2004;22:64–8.

    Google Scholar 

  101. Trousseau A. Phlegmasia alba dolens. Clinique Médicale de l’Hôtel-Dieu de París. 1865;3:654–712.

    Google Scholar 

  102. Tincani A, Taraborelli M, Cattaneo R. Antiphospholipid antibodies and malignancies. Autoimmun Rev. 2010;9:200–2.

    Article  CAS  PubMed  Google Scholar 

  103. Dogan M, Demirkazik A. Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor. Support Cancer Ther. 2005;3:28–34.

    Article  CAS  PubMed  Google Scholar 

  104. Reinstein E, Shoenfeld Y. Antiphospholipid syndrome and cancer. Clin Rev Allergy Immunol. 2007;32:184–7.

    Article  PubMed  Google Scholar 

  105. Stasi R, Stipa E, Masi M, et al. Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin’s lymphoma. Thromb Haemost. 1993;70:568–72.

    CAS  PubMed  Google Scholar 

  106. Yoon KH, Wong A, Shakespeare T, Sivalingam P. High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus. 2003;12:112–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA

    Ozan Unlu

  2. Department of Rheumatology, New York University School of Medicine, New York, NY, USA

    Vinicius Domingues

  3. Department of Obstetrics, Hospital Universitario Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

    Guilherme Ramires de Jesús

  4. Nancy University Hospital, Vascular Medicine Division; and Regional Competence Centre for Rare Vascular and Systemic Autoimmune Diseases, Vandoeuvre-lès-Nancy Cedex, France

    Stéphane Zuily

  5. Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain

    Gerard Espinosa & Ricard Cervera

  6. Hospital University Pedro Ernesto, Internal Medicine, Rio de Janeiro, Brasil

    Roger Abramino Levy

  7. Department of Cardio-Vascular Medicine, Vascular Medicine Division; and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Nancy University Hospital, Insitut Lorrain du Coeur et des Vaisseaux, Vandoeuvre-lès-Nancy Cedex, France

    Denis Wahl

  8. Department of Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA

    Doruk Erkan & Michael D. Lockshin

Authors
  1. Ozan Unlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vinicius Domingues
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guilherme Ramires de Jesús
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stéphane Zuily
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gerard Espinosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ricard Cervera
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Roger Abramino Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Denis Wahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Doruk Erkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Michael D. Lockshin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ozan Unlu or Vinicius Domingues .

Editor information

Editors and Affiliations

  1. The Barbara Volcker Center for Women and Rheumatic Diseases, Associate Attending Physician, Hospital for Special Surgery, Associate Professor of Medicine, Weill Cornell Medicine, New York, New York, USA

    Doruk Erkan

  2. The Barbara Volcker Center for Women and Rheumatic Diseases, Attending Physician, Hospital for Special Surgery, Professor of Medicine and Obstetrics-Gynecology, Weill Cornell Medicine, New York, New York, USA

    Michael D. Lockshin

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Unlu, O. et al. (2017). Definition and Epidemiology of Antiphospholipid Syndrome. In: Erkan, D., Lockshin, M. (eds) Antiphospholipid Syndrome. Springer, Cham. https://doi.org/10.1007/978-3-319-55442-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-55442-6_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-55440-2

  • Online ISBN: 978-3-319-55442-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation